Analysts have given a mean recommendation of 2.10 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Juno Therapeutics has a consensus rating of "Hold" and a consensus target price of $30.81. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since January 21, 2017 and is downtrending. The company has a market capitalization of $7,740.00, a PE ratio of -20.00 and a beta of 2.32. Juno Therapeutics has a 52 week low of $19.07 and a 52 week high of $74.35.
When we see the company's Volatility, it now has a monthly volatility of 4.89% and weekly volatility of 6.20%.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.07.
Juno Therapeutics Inc. (NASDAQ:JUNO) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The company's revenue was up 115.4% compared to the same quarter last year. research analysts forecast that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.
For the current quarter, 13 analysts are projecting a mean EPS of $-1.01/share.
US Oil Production to Hit New Record in 2018
This, combined with healthy oil demand, has pushed up crude by nearly 15 percent since early December. Distillates - used to make diesel and heating oils - fell by 3.9 million barrels.
In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 270,250 shares of the business's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the sale, the director now owns 824,985 shares of the company's stock, valued at $24,246,309.15. The disclosure for this sale can be found here. The stock exchanged hands with 8,430,790 numbers of shares compared to its average daily volume of 2.64M shares. It increased, as 26 investors sold Juno Therapeutics, Inc. shares while 46 reduced holdings. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company's stock worth $347,000 after purchasing an additional 200 shares during the last quarter.
Juno Therapeutics Inc. shares increased 40.72 percent over the past week and rose 56.78 percent over the previous month. Celgene said the deal, expected to close in the first quarter of this year, should add 50 cents a share to adjusted per-share earnings in 2018. Aperio Group LLC grew its holdings in shares of Juno Therapeutics by 4.2% in the third quarter. Over the last quarter, insiders have sold 365,337 shares of company stock worth $17,540,499. Schwab Charles Investment Management Inc. now owns 378,195 shares of the biopharmaceutical company's stock valued at $17,288,000 after purchasing an additional 53,821 shares during the period. Institutional investors and hedge funds own 69.94% of the company's stock.
COPYRIGHT VIOLATION NOTICE: "Juno Therapeutics (JUNO) Lowered to "Neutral" at Citigroup" was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune.
Biopharmaceutical giant Celgene will purchase Juno Therapeutics for $9 billion in a move to expand in the increasingly competitive cancer treatment landscape, reports Bloomberg.